LINC01836 is a new biomarker for the diagnosis and prognosis of
colorectal cancer

doi:10.3760/cma.j.issn.1007-1245.2022.03.017

International Medicine and Health Guidance News ›› 2022, Vol. 28 ›› Issue (3): 363-367.DOI: 10.3760/cma.j.issn.1007-1245.2022.03.017

• Laboratory Medicine Column • Previous Articles Next Articles

LINC01836 is a new biomarker for the diagnosis and prognosis of colorectal cancer

Zhao Wenzhen¹, Lin Yuning²

¹Xiamen Medical College, Xiamen 361023, China;
²Center of Medical Laboratory, Xiamen Humanity Hospital Affiliated to Fujian Medical University, Xiamen 361009, China

Received:2021-11-18 Online:2022-02-01 Published:2022-03-01
Contact: Lin Yuning, Email: 287170933@qq.com
Supported by:
Medical and Health Guidance Project in Xiamen in 2020 (3502Z20209072)

LINC01836是一种新的结直肠癌诊断和预后的生物标志物

赵文镇¹ 林宇宁²

¹福建省厦门医学院，厦门　361023；
²福建医科大学附属厦门弘爱医院医学检验中心，厦门　361009

通讯作者: 林宇宁，Email：287170933@qq.com
基金资助:
2020年厦门市医疗卫生指导性项目（3502Z20209072）

Abstract

Abstract:

Objective　To explore the relationship between LINC01836 and colorectal cancer. Methods　A retrospective study was performed through the Cancer Genome Atlas (TCGA) database. The V23.0 gene expression profile data of colorectal cancer patients released on April 7, 2020 in the TCGA database were downloaded. The relationship between clinicopathological features and LINC01836 expression was evaluated by Wilcoxon rank sum test, chi square test, Fisher test, and logistic regression analysis. Receiver operating characteristic curve (ROC) was drawn to evaluate the diagnostic value of LINC01836 for colorectal cancer. Kaplan-Meier survival analysis was used to evaluate the effect of LINC01836 on the prognosis of patients with colorectal cancer. Results　The expression of LINC01836 in colorectal cancer was statistically different in different N stage (χ²=6.68, P=0.035), M stage (χ²=9.32, P=0.002), pathological stage (χ²=12.6, P<0.001), lymphatic invasion (χ²=11.82, P<0.001), and colonic polyps (χ²=4.51, P=0.034). Logistic regression showed that the high expression of LINC01836 was associated with N stage progression (OR=1.469, P = 0.017), M stage progression (OR=2.131, P=0.002), pathological stage progression (OR=1.580, P=0.005), lymphatic invasion (OR=1.826, P<0.001), and colonic polyps (OR=0.576, P=0.025). ROC showed that LINC01836 had significant diagnostic efficacy in distinguishing colorectal cancer tissues from adjacent normal tissue [area under curve (AUC)=0.907] and normal tissue (AUC=0.899). Kaplan-Meier survival analysis showed that the high expression of LINC01836 was associated with the low overall survival rate in the patients with colorectal cancer (P=0.002). Conclusions　LINC01836 is highly expressed in colorectal cancer and is related to a variety of clinicopathological features of colorectal cancer patients. It may become a new biomarker with potential application value for colorectal cancer.

Key words: Biomarker, Colorectal cancer, lncRNA, LINC01836

摘要： 目的　探索LINC01836和结直肠癌之间的关系。方法　通过癌症基因组图谱（The Cancer Genome Atlas，TCGA）数据库进行回顾性研究。在TCGA数据库下载2020年4月7日发布的V23.0版本的结直肠癌患者基因表达谱数据，通过Wilcoxon秩和检验、卡方检验、Fisher检验和logistic回归分析评估临床病理特征与LINC01836表达之间的关系。绘制受试者工作特征曲线（receiver operating characteristic curve，ROC）用于评价LINC01836对结直肠癌的诊断价值。Kaplan-Meier生存分析用于评估LINC01836对结直肠癌患者预后的影响。结果　结直肠癌中LINC01836表达在不同的N分期（χ²=6.68，P=0.035）、M分期（χ²=9.32，P=0.002）、病理分期（χ²=12.60，P<0.001）、淋巴侵犯（χ²=11.82，P<0.001）和结肠息肉（χ²=4.51，P=0.034）的差异均有统计学意义。logistics回归分析结果显示：高表达的LINC01836与N分期进展（OR=1.469，P=0.017）、M分期进展（OR=2.131，P=0.002）、病理分期进展（OR=1.580，P=0.005）、淋巴侵犯（OR=1.826，P<0.001）、结肠息肉相关（OR=0.576，P=0.025）。ROC表明LINC01836对区分结直肠癌组织与癌旁正常组织［曲线下面积（AUC）=0.907］和正常组织（AUC=0.899）均具有显著的诊断效能。Kaplan-Meier生存分析表明，LINC01836高表达与结直肠癌患者总体生存率低有关（P=0.002）。结论　LINC01836在结直肠癌组织中高表达，并与结直肠癌患者多种临床病理特征相关，可能成为结直肠癌新的有潜在应用价值的生物标志物。

关键词: 生物标志物, 结直肠癌, lncRNA, LINC01836

Zhao Wenzhen, Lin Yuning. LINC01836 is a new biomarker for the diagnosis and prognosis of colorectal cancer [J]. International Medicine and Health Guidance News, 2022, 28(3): 363-367.

赵文镇, 林宇宁.

LINC01836是一种新的结直肠癌诊断和预后的生物标志物 [J]. 国际医药卫生导报, 2022, 28(3): 363-367.

References

[1] Erratum: global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2020, 70(4):313. DOI: 10.3322/caac.21609.

[2] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1):7-30. DOI: 10.3322/caac.21442.

[3] Brenner H, Kloor M, Pox CP. Colorectal cancer[J]. Lancet, 2014,383(9927):1490-1502. DOI: 10.1016/S0140- 6736(13)61649-9.

[4] Effendi-Ys R. Cancer stem cells and molecular biology test in colorectal cancer: therapeutic implications [J]. Acta Med Indones, 2017,49(4):351-359.

[5] Oliveira DM, Grillone K, Mignogna C, et al. Correction to: next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene [J]. J Exp Clin Cancer Res, 2018, 37(1):112. DOI: 10.1186/s13046-018-0776-5.

[6] García-Alfonso P, García-Foncillas J, Salazar R, et al. Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology [J]. Clin Transl Oncol, 2015, 17(4):264-273. DOI: 10.1007/s12094-014-1252-0.

[7] Mody K, Bekaii-Saab T. Clinical trials and progress in metastatic colon cancer [J]. Surg Oncol Clin N Am, 2018, 27(2):349-365. DOI: 10.1016/j.soc.2017.11.008.

[8] Puerta-García E, Cañadas-Garre M, Calleja-Hernández MÁ. Molecular biomarkers in colorectal carcinoma [J]. Pharmacogenomics, 2015, 16(10): 1189-222. DOI: 10.2217/PGS.15.63.

[9] Raveendra BL, Swarnkar S, Avchalumov Y, et al. Long noncoding RNA GM12371 acts as a transcriptional regulator of synapse function [J]. Proc Natl Acad Sci U S A, 2018, 115(43): E10197-E10205. DOI: 10.1073/pnas. 1722587115.

[10] Dong Z, Zhang A, Liu S, et al. Aberrant methylation-mediated silencing of lncRNA MEG3 functions as a ceRNA in esophageal cancer [J]. Mol Cancer Res, 2017, 15(7): 800-810. DOI: 10.1158/1541-7786.MCR-16-0385.

[11] Hanahan D, Weinberg RA. The hallmarks of cancer [J]. Cell, 2000, 100(1): 57-70. DOI: 10.1016/s0092-8674(00)81683-9.

[12] Vivian J, Rao AA, Nothaft FA, et al. Toil enables reproducible, open source, big biomedical data analyses [J]. Nat Biotechnol, 2017, 35(4):314-316. DOI: 10.1038/nbt.3772.

[13] Fu X, Huang Y, Fan X, et al. Demographic trends and KRAS/BRAF^V600E mutations in colorectal cancer patients of South China: a single-site report [J]. Int J Cancer, 2019, 144(9):2109-2117. DOI: 10.1002/ijc.31973.

[14] Ørom UA, Derrien T, Beringer M, et al. Long noncoding RNAs with enhancer-like function in human cells [J]. Cell, 2010, 143(1): 46-58. DOI: 10.1016/j.cell.2010.09.001.

[15] Yu G, Wang LG, Han Y, et al. Cluster profiler: an R package for comparing biological themes among gene clusters [J]. OMICS, 2012,16(5): 284-287. DOI: 10.1089/omi.2011. 0118.

[16] Saus E, Brunet-Vega A, Iraola-Guzmán S, et al. Long non-coding RNAs as potential novel prognostic biomarkers in colorectal cancer [J]. Front Genet, 2016, 7:54. DOI: 10.3389/fgene.2016.00054.

[17] Ye LC, Zhu X, Qiu JJ, Xu J, Wei Y. Involvement of long non-coding RNA in colorectal cancer: from benchtop to bedside (review) [J]. Oncol Lett, 2015, 9(3):1039-1045. DOI: 10.3892/ol.2015.2846.

[18] 张锐江,吴桂堂,郭亮,等.腹腔镜结直肠癌根治术治疗结直肠癌患者的疗效与安全性[J].国际医药卫生导报,2020,26(16):2341-2344. DOI:10.3760/cma.j.issn.1007-1245. 2020.16.004.

[19] 郭厚基.免疫检查点抑制剂治疗结直肠癌的研究进展[J].国际医药卫生导报,2021,27(11):1675-1679. DOI:10.3760/cma.j.issn.1007-1245.2021.11.023.

LINC01836 is a new biomarker for the diagnosis and prognosis of colorectal cancer

LINC01836是一种新的结直肠癌诊断和预后的生物标志物

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 1

Recommended Articles

Metrics